How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Pentosan polysulfate sodium for treating bladder pain syndrome

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about pentosan polysulfate sodium

Marketing authorisation indication

Pentosan polysulfate sodium (Elmiron, Consilient Health) has a marketing authorisation for treating 'bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition'.

Dosage in the marketing authorisation

300 mg/day taken as 1×100 mg capsule orally 3 times daily.

Treatment is stopped if no improvement is reached 6 months after starting treatment. In people whose condition responds, treatment should be continued as long as the response is maintained.

Price

A pack of 90 capsules (100 mg each) costs £450.

The company has a commercial arrangement, which would have applied if the technology had been recommended.